In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

SR One leads antibody company f-star’s €15mm Series B round

Executive Summary

In what is assumed to be its Series B round, f-star GMBH (technology that adds more binding sites into full antibodies and antibody fragments) has raised €15mm ($22mm). Led by first-time backer SR One, the financing also included all existing shareholders: Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures, and MP Healthcare Venture Management. Members of SR One and TVM have joined the company’s supervisory board. The biotech will use the money on preclinical studies of its first drug candidates in preparation for IND filing. Including the Series B funding, f-star has amassed €34mm in venture capital to date.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies